The Diaxonhit group is a French fully integrated leader in the field of in-vitro diagnostic with expertise ranging from discovery to the commercialization of specialty diagnostic products.
As a result of the acquisition of InGen BioSciences by Exonhit, the new group benefits from the complementary capabilities derived from both companies’ business models, activities and know-how.
Diaxonhit immediately focus its efforts on the continued development of its distribution activities, leveraging the sales organization that is already in place, and accelerating the development of its high added value proprietary innovative diagnostic products.
Diaxonhit owns a broadened and diversified portfolio of proprietary diagnostic products in three specialty areas : transplantation, infectious diseases and cancer diagnosis.
The group is currently marketing its first proprietary test, TQS® (Tetanus Quick Stick), used in emergency clinics for the evaluation of the protective status of a patient against tetanus. Additionally, Diaxonhit continues the developement of its innovative molecular diagnostics products.
The group has a balanced development strategy, with in-house research programs and strategic collaborations.
Contact
65 Boulevard Masséna
F-75013 PARIS – FRANCE
Tel: +33 (0) 1 53 94 77 00
Fax: +33 (0) 1 53 94 77 07
Email: Pleaseforward@diaxonhit.com
Web: www.diaxonhit.com
The CEO of Diaxonhit Group, a fully integrated French leader in in vitro diagnostics, discusses the company’s strategic focus on specialty vitro diagnostics, his perspective on the challenge of consolidation…
We need to raise our voice and say: look at us too, there are also mid-sized pharma companies out there looking for something different In conversation at BIO 2026 in…
The rare disease landscape is becoming increasingly sophisticated, demanding not only scientific innovation but also new approaches to access, evidence generation and patient support. Recordati Rare Diseases has built its…
Sanofi’s new CEO Belén Garijo has taken the reins of a company with healthy growth, but three recent late-stage clinical trial failures and a looming patent cliff for its biggest…
Complementing the Lyon region’s strong industrial footprint is a dense network of hospital facilities, only bettered by Paris on the national level. Across 13 hospitals in the Hospices Civils de…
The Auvergne-Rhône-Alpes region, with Lyon at its heart, is France’s industrial heartland. Hosting over 500,000 manufacturing and manufacturing-related jobs, AURA is also the nation’s top destination the production of biologics,…
European biotech’s recent struggles are well documented. Deep-pocketed investors with sufficient risk tolerance to fund potentially breakout companies are thin on the ground, and Europe is losing touch with both…
Lyon’s leading biotechs have caught the eye of global pharma in recent years, with two major acquisitions attesting to the quality and sophistication of the ecosystem and laying a path…
Lyon – recently announced as the host of BIO-Europe Spring 2027 – has long played a vital role in global health and, in 2026, it stands as one of Europe’s…
Ophthalmology is a booming niche, with investment flowing in, M&A up, and a burgeoning cast of biotechs – including the three European leaders profiled below – vying for a share…
France and Denmark have a rich history of healthcare collaboration, from basic research to clinical trials, as well as major manufacturing investments. What links these two nations, and what are…
France is considered among the leading rare disease markets worldwide, both scientifically and organisationally. The country has cultivated a fully-fledged supporting ecosystem for rare conditions that is today regarded as…
France’s historical contribution to medical research is almost unparalleled globally, with 13 winners of the annual Nobel Prize for Physiology or Medicine, and even more for Chemistry. Most famously, Louis…
See our Cookie Privacy Policy Here
